Physician profile
Michael Savetsky
NPI 1255598819
$63,006.81
in general payments reported to CMS, 2019-2025
19 companies · $2,530 in 2025
The $2,530 reported for 2025 was more than what 87% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $13K · 2021: $5,182 · 2022: $10K · 2023: $390 · 2024: $791 · 2025: $2,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,875 · Food and Beverage: $1,736 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,875.00 |
| Food and Beverage | $1,736.26 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $41,852.53 | 2019-2021 | |
| Oyster Point Pharma, INC. | $9,987.37 | 2022-2023 | Tyrvaya |
| Mallinckrodt Enterprises LLC | $3,944.49 | 2019 | |
| Mallinckrodt Hospital Products INC. | $2,530.06 | 2020-2024 | Acthar |
| Tarsus Pharmaceuticals, INC. | $2,522.83 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $664.65 | 2019-2025 | Cequa |
| Alcon Vision LLC | $452.39 | 2019-2023 | Argos, Rocklatan, Hydrus Microstent |
| Amgen INC. | $245.99 | 2024 | Tepezza |
| Dompe US, INC. | $198.18 | 2021-2025 | Oxervate |
| Horizon Therapeutics Plc | $183.37 | 2023 | Tepezza |
| Allergan, INC. | $171.58 | 2019-2022 | |
| Sight Sciences, INC. | $97.36 | 2024-2025 | Omni Surgical System |
| Novartis Pharmaceuticals Corporation | $40.34 | 2019 | |
| Glaukos Corporation | $29.56 | 2021 | |
| Eyevance Pharmaceuticals LLC | $28.71 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $27.53 | 2025 | Tecnis Iol, Tecnis Iol |
| Shire North American Group INC | $18.81 | 2019 | |
| Aerie Pharmaceuticals, INC. | $11.06 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Savetsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.